FDA Approves Livalo for Primary Hypercholesterolemia and Combined Dyslipidemia
FDA Approves Livalo for Primary Hypercholesterolemia and Combined Dyslipidemia
August 4, 2009
MONTGOMERY, Ala. and MORRISVILLE, N.C., Aug. 3 /PRNewswire/ -- Kowa
Research Institute (KRI) based in Morrisville, NC and Kowa
Pharmaceuticals America, Inc. (KPA), a privately-held specialty
pharmaceutical company headquartered in Montgomery, AL, announced
today that the U.S. Food and Drug Administration (FDA) has approved
Livalo (pitavastatin), a potent HMG-CoA reductase inhibitor (statin),
for the primary treatment of hypercholesterolemia and combined
dyslipidemia.
August 4, 2009
MONTGOMERY, Ala. and MORRISVILLE, N.C., Aug. 3 /PRNewswire/ -- Kowa
Research Institute (KRI) based in Morrisville, NC and Kowa
Pharmaceuticals America, Inc. (KPA), a privately-held specialty
pharmaceutical company headquartered in Montgomery, AL, announced
today that the U.S. Food and Drug Administration (FDA) has approved
Livalo (pitavastatin), a potent HMG-CoA reductase inhibitor (statin),
for the primary treatment of hypercholesterolemia and combined
dyslipidemia.
Comentarios
Publicar un comentario